Topics

Companies Related to "MorphoSys MorphoSys Biopharma Announce First Patient Dosed Phase" [Most Relevant Company Matches] RSS

07:44 EDT 20th September 2019 | BioPortfolio

Here are the most relevant search results for "MorphoSys MorphoSys Biopharma Announce First Patient Dosed Phase" found in our extensive corporate database of over 50,000 company records.

Showing "MorphoSys MorphoSys Biopharma Announce First Patient Dosed Phase" Companies 1–25 of 4,200+

Extremely Relevant

MorphoSys GmbH

MorphoSys AG, located in Martinsried/Munich, is one of the world's leading biotechnology companies focusing on fully human antibodies. With its unique technologies, MorphoSys is developing the next generation of antibodies, which can be used to treat diseases and for research and diagnostics purposes. Numerous partnerships have already been entered into with well-known companies from the pharmaceu...


Biogenesis Ltd

Biogenesis is a recognized leader in the supply of monoclonal and polyclonal antibodies and custom manufacturing services to IVD manufacturers, pharmaceutical companies and life science researchers around the globe. For more than 20 years, these customers have chosen Biogenesis for its quality, reliability, and innovation. Our ongoing commitment to quality products and services is demonstrated by ...

MorphoSys AG,

MorphoSys AG, located in Martinsried/Munich, is one of the world's leading biotechnology companies focusing on fully human antibodies. With its unique technologies, MorphoSys is developing the next generation of antibodies, which can be used to treat diseases and for research and diagnostics purposes. Numerous partnerships have already been entered into with well-known companies from the pharmaceu...


MorphoSys AG

MorphoSys AG, located in Martinsried/Munich, is one of the world's leading biotechnology companies focusing on fully human antibodies. With its unique technologies, MorphoSys is developing the next generation of antibodies, which can be used to treat diseases and for research and diagnostics purposes. Numerous partnerships have already been entered into with well-known companies from the pharmaceu...

Relevant

Antibodies by Design

Antibodies by Design uses proven MorphoSys recombinant antibody technology to provide high quality monoclonal antibodies to its customers in record time. The HuCAL GOLD® library contains over 15 billion unique human antibody genes in Fab format. This wealth and diversity of sequences is coupled with proprietary automated screening techniques and advanced data management systems to quickly identif...

Exostar and SAFE-BioPharma Association

SAFE-BioPharma manages the SAFE-BioPharma global digital identity and digital signatures standard, developed for and used extensively throughout the biopharmaceutical industry. LOA 2 satisfies identity-proofing and credential issuing practices acceptable for access to systems where risk of identity fraud is minimized, including patient access to read-only ...

SAFE-BioPharma Association

SAFE-BioPharma Association (www.safe-biopharma.org) is the non-profit association that created and manages the SAFE-BioPharma® digital identity and signature standard for the pharmaceutical and healthcare industries.

Kedrion Biopharma, Inc.

Kedrion Biopharma is an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating and preventing serious diseases, disorders and conditions such as hemophilia, primary immune system deficiencies and Rh-sensitization. Kedrion Biopharma Inc., the U.S. subsidiary of Kedr...

Akebia Therapeutics, Inc.

Akebia Therapeutics is a discovery and development company focused on anemia and vascular disorders. Akebia’s lead program, AKB-6548, an orally bioavailable HIF-prolyl hydroxylase (HIF-PH) inhibitor for patients with anemia, is in phase 2 clinical trials. AKB-6548 potentially promises to be a safer, less expensive, orally dosed pharmaceutical to stimu...

BioTechNews Denmark

TopoTarget and CuraGen Announce Initiation of NCI-sponsored Phase II Clinical Trial with PXD101 for MesotheliomaTopoTarget A/S and CuraGen Corporation announced today the initiation of patient dosing in a Phase II clinical trial evaluating the activity of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of mesothelioma. This trial is being sponsored by the National ...

Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies. For more information on the Company, visit http://www.genesis-biopharma.com.

SAFE-BioPharma Association, LLC

As part of the National Health Information Sharing and Analysis Center (NH-ISAC), SAFE-BioPharma Association, LLC [www.safe-biopharma.org] provides global, high-assurance identity trust for cyber-transactions in the biopharmaceutical and healthcare industries.

TenX Biopharma, Inc.

TenX Biopharma, Inc., is a biopharmaceutical company focused on late stage development and commercialization of novel monoclonal antibody-based cancer therapies. TenX Biopharma acquired global rights to zanolimumab in February, 2010 from Genmab (CO:GEN) in conjunction with a financing led by Zoticon Bioventures. For more information visit www.tenxbiopharma.com.

Rentschler Biopharma SE

Rentschler Biopharma SE, located in Laupheim, Germany, is a leading contract development and manufacturing organization (CDMO) for bioprocess development and manufacturing of biopharmaceuticals as well as for related consulting activities in terms of project management and regulatory support. The Company's clients include innovative biotech companies and m...

DOR BioPharma, Inc.

DOR BioPharma, Inc. (DOR) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec(R) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a comm...

Ansun BioPharma

Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses. Ansun BioPharma has two products in late stage clinical development. FluDaseTM is a first-in-class broad-spectrum investigational therapeutic agent to treat all forms of influenza, including pandemic...

Nexien BioPharma, Inc.

Nexien BioPharma is a US-based pharmaceutical company engaged in the formulation, development and commercialization of cannabinoid pharmaceuticals in accordance with U.S. Food and Drug Administration ("FDA") pre-clinical and clinical pathways, to address a broad range of medical conditions and disorders. For more information, visit Nexien BioPharma’s ...

BioPharma Fund

BioPharma Fund is an investment fund that invests in shares of medical biotechnology companies. Biotechnology companies are developing new drugs for many diseases such as cancer, heart disease, diabetes, AIDS and Alzheimer’s. BioPharma Fund invests in these innovator companies.The Fund is a sub-fund of TONIC Sector Fund SICAV, a Luxembourg-based investment company.BioPharma Fund’s Common Share...

BioPharma Services, Inc.

BioPharma Services Inc. is a Full-Service Contract Research Organization (CRO) specializing in the conduct of Phase I/IIa clinical trials as well as Bioequivalence trials for international pharmaceutical companies worldwide. The company has clinical facilities both in the U.S.A. and in Canada with a total bed capacity of 250 with access to healthy voluntee...

Artax Biopharma

Artax Biopharma is a clinical stage biopharmaceutical company developing breakthrough therapies for autoimmune diseases. Its pipeline of drugs is based on novel science that targets the interaction between T-cell receptors (TCR) and Nck, a key protein involved in T-cell activation. Based in Cambridge, Massachusetts, more information on Artax Biopharma can ...

Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is scheduled to enter Phase III trials in 2...

KBI Biopharma, Inc.

KBI Biopharma, located in Durham, NC, is a leading contract development organization for the biopharmaceutical industry, working with companies across the globe focused on protein-based products. KBI delivers expert and integrated biophysical and biochemical protein characterization, formulation and process development and cGMP manufacturing of recombinant protein Active Pharmaceutical Ingredients...

Biopharma Services Inc.

BioPharma Services Inc. is a physician-owned, physician-run, US FDA-inspected, UK MHRA-inspected, and Health Canada-inspected International Contract Research Organization (CRO) which specializes in the conduct of Phase I/IIa clinical trials, including FIM trials, BE studies and Bioanalysis, for international pharmaceutical and biotech companies from the US...

SAFE-BioPharma Association Taigle Becomes SAFE-BioPharma Vendor Partner

The corrected release reads:

RxCrossroads™ by McKesson

RxCrossroads™ by McKesson creates flexible, connected solutions for life sciences companies. Its solutions focus on increasing access, adherence, and safe use conditions, seamlessly connecting patients to their therapies, and enabling them to thrive at every step in their care journey. Through expert teams, deep market insights and innovative technolo...


More From BioPortfolio on "MorphoSys MorphoSys Biopharma Announce First Patient Dosed Phase"

Quick Search

Corporate Database Quicklinks